Maxim Group analyst Anthony Vendetti has reiterated their bullish stance on SRTS stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anthony Vendetti has given his Buy rating due to a combination of factors, including Sensus Healthcare’s strong performance in the first quarter of 2025, where the company exceeded revenue expectations despite lower earnings per share. The company’s strategic shift towards the ‘Fair Deal’ program, which is expected to drive growth through increased device installations and utilization, is a significant factor in this rating.
Additionally, Sensus Healthcare’s financial health, with a substantial cash reserve and no debt, positions it well for future growth opportunities, particularly in acquisitions. The anticipated approval of the TransDermal Infusion (TDI) 510(k) application by the third quarter of 2025 is also seen as a potential growth catalyst. Despite lowering revenue and earnings estimates and reducing the price target, the continued momentum in device placements and the expansion of the ‘Fair Deal’ program support the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.